



1614 #6
12/16/02
PATENT APPLICATION

TECH CENTER 1600/2900

DEC 03 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Chen et al.

Serial No.: 10/046,526 ✓

Group Art Unit No.: 1614

Filed: January 10, 2002 ✓

Examiner: n/a

For: Substituted Arylamine Derivatives and Methods of Use ✓

Docket No.: A-735A

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Under the guidelines of 37 C.F.R. 1.97, applicants submit a copy of each of the references listed on the attached supplemental PTO-1449 (Modified) form for consideration by the Examiner.

Applicants, by the undersigned attorney/agent, certify that each item contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, (copy of which is attached hereto) and not more than three months pursuant to 37 C.F.R. 1.97(e)(1) prior to the filing of this statement.

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc. An original and one copy of this paper are enclosed.

Respectfully submitted,

Joseph W. Bulock
Attorney/Agent for Applicant(s)
Registration No.: 37,103
Phone: (805) 447-7966
Date: November 21, 2002

Please send all future correspondence to:
U.S. Patent Operations/ JWB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

11/22/2002
Date

Signature